The CWRU/UHC CFAR Immune Function Core is dedicated to providing CFAR members and other investigators in the CWRU/UHC research community convenient access to the latest techniques and expertise for evaluation of immune function. Services provided by the Immune Function Core include: flow cytometric examination of cell phenotype and intracellular cytokine expression, evaluation of cellular cytokine and chemokine production by ELISA techniques, and the identification and quantification of antigen-specific cells by ELISPOT analysis. Investigators are trained in the use of core machinery and may use core resources on an hourly charge basis. To enhance access, investigators also may elect to have core personnel perform any core assays on single or multiple research samples on a fee-for-service basis. The core also coordinates purchase of reagents and ELISA kits for CFAR members at significant negotiated discounts, as well as maintaining a repository of immunologic reagents that can be purchased in small quantities for pilot or test projects. This core has been used by 20 CFAR investigators and investigators at other sites to support 32 different projects including 15 ACTG studies. In collaboration with the CWRU/UHC Ireland Cancer Center, the CFAR Immune Function Core is equipping a shared purchase high-speed cell sorter to permit rapid sorting of cells under BL-3 containment conditions. In addition to performing assays and providing access to equipment, the Immune Function Core is prepared to respond to investigators' needs by the development of new immunologic assays to support HIV research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-15
Application #
7636810
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
15
Fiscal Year
2008
Total Cost
$221,667
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications